文献速递肝肾功能剂量调整药物不良反应与药物警戒

Crisugabalin治疗神经病理性疼痛的转化开发

Translational development of crisugabalin for neuropathic pain.
PubMed 文献 · Br J Clin Pharmacol · 2026-09-25

本文对Crisugabalin(HSK16149)的分子结构、动物药理、I期临床及随机临床试验进行转化综述。该药为新一代α2δ配体,在DPNP和PHN中40-80 mg/日可显著降低疼痛强度,头晕为最常见剂量相关不良事件,肾功能不全需考虑剂量调整。

要点

  • Crisugabalin对α2δ1的解离慢于α2δ2,动物中镇痛与运动损害剂量分离优于普瑞巴林。
  • I期显示Tmax约1.5-1.7 h,暴露呈剂量比例,主要经肾排泄,肾功能减退需调整剂量。
  • DPNP和PHN临床试验中40-80 mg/日显著降低疼痛强度,头晕为最常见剂量相关不良事件。

核心结论

  • 现有证据支持Crisugabalin作为类别优化策略,在DPNP和PHN中具有一致的短期疗效和可预测的临床药理特征。

研究设计与样本

  • 转化综述,涵盖分子/结构研究、体内药理学与行为安全性评估、I期临床药理及DPNP和PHN随机临床试验,检索截至2026年6月。

主要发现

  • 结构动力学研究显示Crisugabalin稳定结合α2δ1位点,且从α2δ1解离慢于α2δ2。
  • 啮齿类模型中Crisugabalin具镇痛效果,镇痛与运动损害剂量间隔较普瑞巴林更宽,标准范式下无明显滥用倾向信号。
  • I期数据显示Tmax约1.5-1.7 h,暴露呈剂量比例,轻微蓄积,主要经肾排泄。
  • 高脂餐延迟吸收但不显著改变总暴露,肾功能不全时暴露呈分级增加。
  • DPNP的II/III期无缝适应性试验和PHN确证性III期试验显示40-80 mg/日显著降低疼痛强度,头晕为最常见剂量相关不良事件。

关键数值与推荐

  • DPNP和PHN临床试验中Crisugabalin 40-80 mg/日显著降低疼痛强度。
  • 肾功能下降时暴露分级增加,支持考虑剂量调整。

临床怎么用

  • 临床用于DPNP和PHN时可考虑40-80 mg/日,需关注头晕。
  • 肾功能减退患者应根据肾功能调整剂量。

局限性

  • 证据主要来自中国人群,外推性受限。
  • 缺乏长期结局数据。
  • 与现有疗法的比较有效性尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Crisugabalin (HSK16149) is a next-generation α2δ ligand developed to preserve the mechanistic rationale of gabapentinoids while refining target engagement and exposure-related tolerability constraints. We performed a translational review of molecular/structural studies, in vivo pharmacology and behavioural safety assessments, phase I clinical pharmacology and randomized clinical trials in diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN), with searches across major bibliographic databases and trial registries updated through June 2026. Evidence was synthesized qualitatively along a molecular-to-clinical sequence. Structural and kinetic studies indicate stable engagement of the α2δ1 binding site, with slower dissociation from α2δ1 than from α2δ2. In rodent models, crisugabalin demonstrated antinociceptive efficacy with a wider separation between antinociceptive and motor-impairing doses relative to pregabalin and no clear abuse liability signals across standard paradigms. Human phase I data show rapid absorption (Tmax ~ 1.5-1.7 h), dose-proportional exposure, slight accumulation and predominant renal elimination. A high-fat meal delayed absorption without materially changing overall exposure, whereas renal impairment produced graded exposure increases supporting consideration of dose adjustment as renal function declines. Clinically, a seamless adaptive phase II/III trial in DPNP and a confirmatory phase III trial in PHN demonstrated significant reductions in pain intensity at 40-80 mg/day; dizziness was the most frequent dose-related adverse event. Current evidence supports crisugabalin as a class-refinement strategy with consistent short-term efficacy in DPNP and PHN and predictable clinical pharmacology. Generalizability beyond Chinese populations, longer-term outcomes and comparative effectiveness relative to established therapies remain key gaps.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. João RB, Tagore Chan JO, Araújo LM, et al. Translational development of crisugabalin for neuropathic pain. Br J Clin Pharmacol. 2026. PMID: 42788255. doi:10.1002/bcp.70821

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。